Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases

Somatic missense mutations in PIK3CA, which encodes the p110α catalytic subunit of phosphoinositide 3-kinases, occur frequently in human cancers. Activating mutations spread across multiple domains, some of which are located at inhibitory contact sites formed with the regulatory subunit p85α. PIK3R1, which encodes p85α, also has activating somatic mutations. We find a strong correlation between lipid kinase and lipid-binding activities for both wild-type (WT) and a representative set of oncogenic mutant complexes of p110α/p85α. Lipid binding involves both electrostatic and hydrophobic interactions. Activation caused by a phosphorylated receptor tyrosine kinase (RTK) peptide binding to the p85α N-terminal SH2 domain (nSH2) induces lipid binding. This depends on the polybasic activation loop as well as a conserved hydrophobic motif in the C-terminal region of the kinase domain. The hotspot E545K mutant largely mimics the activated WT p110α. It shows the highest basal activity and lipid binding, and is not significantly activated by an RTK phosphopeptide. Both the hotspot H1047R mutant and rare mutations (C420R, M1043I, H1047L, G1049R and p85α-N564D) also show increased basal kinase activities and lipid binding. However, their activities are further enhanced by an RTK phosphopeptide to levels markedly exceeding that of activated WT p110α. Phosphopeptide binding to p110β/p85α and p110δ/p85α complexes also induces their lipid binding. We present a crystal structure of WT p110α complexed with the p85α inter-SH2 domain and the inhibitor PIK-108. Additional to the ATP-binding pocket, an unexpected, second PIK-108 binding site is observed in the kinase C-lobe. We show a global conformational change in p110α consistent with allosteric regulation of the kinase domain by nSH2. These findings broaden our understanding of the differential biological outputs exhibited by distinct types of mutations regarding growth factor dependence, and suggest a two-tier classification scheme relating p110α and p85α mutations with signalling potential.

[1]  J. Bayascas,et al.  PDK1: the major transducer of PI 3-kinase actions. , 2010, Current topics in microbiology and immunology.

[2]  Carlo Rago,et al.  Mutant PIK3CA promotes cell growth and invasion of human cancer cells. , 2005, Cancer cell.

[3]  N. Verdaguer,et al.  Ca2+ bridges the C2 membrane‐binding domain of protein kinase Cα directly to phosphatidylserine , 1999 .

[4]  J. Engelman,et al.  H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation via heregulin production and activation of HER3 , 2010, Oncogene.

[5]  M. Lemmon,et al.  Determining selectivity of phosphoinositide-binding domains. , 2006, Methods.

[6]  Fabrice Gorrec,et al.  The p110delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. , 2010, Nature chemical biology.

[7]  Yosef Yarden,et al.  Roles for growth factors in cancer progression. , 2010, Physiology.

[8]  B. González,et al.  Structure of a human inositol 1,4,5-trisphosphate 3-kinase: substrate binding reveals why it is not a phosphoinositide 3-kinase. , 2004, Molecular cell.

[9]  Roger L. Williams,et al.  Structure of Lipid Kinase p110β/p85β Elucidates an Unusual SH2-Domain-Mediated Inhibitory Mechanism , 2011, Molecular cell.

[10]  Roger L. Williams,et al.  Mapping the Phospholipid-binding Surface and Translocation Determinants of the C2 Domain from Cytosolic Phospholipase A2 * , 1999, The Journal of Biological Chemistry.

[11]  N. Verdaguer,et al.  Ca(2+) bridges the C2 membrane-binding domain of protein kinase Calpha directly to phosphatidylserine. , 1999, The EMBO journal.

[12]  K. Kinzler,et al.  A frequent kinase domain mutation that changes the interaction between PI3Kα and the membrane , 2009, Proceedings of the National Academy of Sciences.

[13]  B. Margolis,et al.  Phosphatidylinositol 3′‐kinase is activated by association with IRS‐1 during insulin stimulation. , 1992, The EMBO journal.

[14]  Bert Vogelstein,et al.  The Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations , 2007, Science.

[15]  R. Owens,et al.  Generation of baculovirus vectors for the high‐throughput production of proteins in insect cells , 2008, Biotechnology and bioengineering.

[16]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[17]  Jeffrey A. Engelman,et al.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations , 2009, Nature Reviews Cancer.

[18]  Jeffrey Wyckoff,et al.  Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase. , 2009, Cancer research.

[19]  T. Franke,et al.  PI3K/Akt: getting it right matters , 2008, Oncogene.

[20]  Li Zhao,et al.  Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms , 2008, Proceedings of the National Academy of Sciences.

[21]  M. Zvelebil,et al.  Activation Loop Sequences Confer Substrate Specificity to Phosphoinositide 3-Kinase α (PI3Kα) , 2001, The Journal of Biological Chemistry.

[22]  Wonhwa Cho,et al.  Membrane-protein interactions in cell signaling and membrane trafficking. , 2005, Annual review of biophysics and biomolecular structure.

[23]  W. Cho,et al.  The Molecular Basis of Differential Subcellular Localization of C2 Domains of Protein Kinase C-α and Group IVa Cytosolic Phospholipase A2 * , 2003, The Journal of Biological Chemistry.

[24]  J. Backer,et al.  Regulation of the p85/p110alpha phosphatidylinositol 3'-kinase. Distinct roles for the n-terminal and c-terminal SH2 domains. , 1998, The Journal of biological chemistry.

[25]  Roger L. Williams,et al.  Dynamics of the Phosphoinositide 3-Kinase p110δ Interaction with p85α and Membranes Reveals Aspects of Regulation Distinct from p110α , 2011, Structure.

[26]  S. Egan,et al.  Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation. , 2011, Cancer research.

[27]  N. Pannu,et al.  REFMAC5 for the refinement of macromolecular crystal structures , 2011, Acta crystallographica. Section D, Biological crystallography.

[28]  N. Verdaguer,et al.  Structural and mechanistic insights into the association of PKCα-C2 domain to PtdIns(4,5)P2 , 2009, Proceedings of the National Academy of Sciences.

[29]  Ralph Weissleder,et al.  Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers , 2008, Nature Medicine.

[30]  L. Cantley,et al.  PI3K pathway alterations in cancer: variations on a theme , 2008, Oncogene.

[31]  K. Shokat,et al.  PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation. , 2008, Cancer research.

[32]  Bernd Giese,et al.  Targeting phosphoinositide 3-kinase: moving towards therapy. , 2008, Biochimica et biophysica acta.

[33]  Guojun Wu,et al.  Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells , 2008, Breast Cancer Research and Treatment.

[34]  M. Lemmon,et al.  Membrane recognition by phospholipid-binding domains , 2008, Nature Reviews Molecular Cell Biology.

[35]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[36]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[37]  G. Prestwich,et al.  Competitive fluorescence polarization assays for the detection of phosphoinositide kinase and phosphatase activity. , 2003, Combinatorial chemistry & high throughput screening.

[38]  M. Loda,et al.  The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Yiling Lu,et al.  AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. , 2009, Cancer cell.

[40]  D. Sgroi,et al.  A Unique Spectrum of Somatic PIK3CA (p110α) Mutations Within Primary Endometrial Carcinomas , 2011, Clinical Cancer Research.

[41]  Pier Paolo Pandolfi,et al.  The PTEN–PI3K pathway: of feedbacks and cross-talks , 2008, Oncogene.

[42]  M. Loda,et al.  The oncogenic properties of mutant p110α and p110β phosphatidylinositol 3-kinases in human mammary epithelial cells , 2005 .

[43]  R. Cardiff,et al.  Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors. , 2011, Cancer research.

[44]  K. Shokat,et al.  Shaping Development of Autophagy Inhibitors with the Structure of the Lipid Kinase Vps34 , 2010, Science.

[45]  I. Jones,et al.  Improving baculovirus recombination. , 2003, Nucleic acids research.

[46]  Marc-André Elsliger,et al.  Rare cancer-specific mutations in PIK3CA show gain of function , 2007, Proceedings of the National Academy of Sciences.

[47]  R. Copeland,et al.  Effects of oncogenic p110α subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase , 2008 .

[48]  L. Cantley,et al.  Phosphoinositide 3-kinase is activated by phosphopeptides that bind to the SH2 domains of the 85-kDa subunit. , 1993, The Journal of biological chemistry.

[49]  J. Gills,et al.  Perifosine: Update on a novel Akt inhibitor , 2009, Current oncology reports.

[50]  Yuval Inbar,et al.  Mechanism of Two Classes of Cancer Mutations in the Phosphoinositide 3-Kinase Catalytic Subunit , 2007, Science.

[51]  S. Baker,et al.  PTEN and the PI3-kinase pathway in cancer. , 2009, Annual review of pathology.

[52]  R. Copeland,et al.  Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase. , 2008, The Biochemical journal.

[53]  M. Girvin,et al.  Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110α and are disrupted in oncogenic p85 mutants , 2009, Proceedings of the National Academy of Sciences.

[54]  Bert Vogelstein,et al.  The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. , 2007, Science.

[55]  T. Kawabe,et al.  Functional analysis of PIK3CA gene mutations in human colorectal cancer. , 2005, Cancer research.

[56]  Geoffrey J. Barton,et al.  Jalview Version 2—a multiple sequence alignment editor and analysis workbench , 2009, Bioinform..

[57]  B. Peters,et al.  Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. , 2009, Cancer cell.

[58]  Christian Ried,et al.  Structural insights into phosphoinositide 3-kinase catalysis and signalling , 1999, Nature.

[59]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[60]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .